Viewing Study NCT03568461

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:45 AM
Ignite Modification Date: 2026-01-27 @ 7:54 PM
Study NCT ID: NCT03568461
Status: COMPLETED
Last Update Posted: 2025-10-07
First Post: 2018-05-24
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Follicular Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Refractory or relapsed Follicular Lymphoma View
None Refractory View
None Relapsed View
None Follicular lymphoma View
None CTL019 View
None Tisagenlecleucel View
None Chimeric antigen receptor View
None CAR19 View
None CAR-T View